{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:40:16Z","timestamp":1783795216692,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.canrad.2023.07.014","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:01:46Z","timestamp":1711548106000},"page":"159-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Acute toxicity in patients with high-risk prostate cancer treated with stereotactic body radiation, with irradiation to the prostate and pelvic nodes"],"prefix":"10.1016","volume":"28","author":[{"given":"S.","family":"Faria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Duclos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Patrocinio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Souhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2023.07.014_bib0080","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.014_bib0085","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. https:\/\/www.nccn.org\/professionals\/physician_gls. (Accessed in August 2022)."},{"key":"10.1016\/j.canrad.2023.07.014_bib0090","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1200\/JCO.2017.75.5371","article-title":"Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer","volume":"36","author":"Pan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.07.014_bib0095","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijrobp.2016.11.007","article-title":"Exploring value from the patient's perspective between modern radiation therapy modalities for localized prostate cancer","volume":"97","author":"Shaverdian","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.07.014_bib0100","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ijrobp.2013.02.006","article-title":"Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: a step forward","volume":"86","author":"Kaidar-Person","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.07.014_bib0105","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1016\/j.prro.2020.06.012","article-title":"Long-term results of moderate hypofractionation to prostate and pelvic nodes plus androgen suppression in high-risk prostate cancer","volume":"10","author":"Faria","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.014_bib0110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.prro.2017.01.003","article-title":"Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy","volume":"7","author":"Faria","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.014_bib0115","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 5","year":"2017"},{"key":"10.1016\/j.canrad.2023.07.014_bib0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.clon.2019.12.002","article-title":"Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localised prostate cancer: ready for prime time?","volume":"32","author":"Cheung","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2023.07.014_bib0125","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.07.014_bib0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JU.0000000000002759","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline. Part III: principles of radiation and future directions","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2023.07.014_bib0135","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ijrobp.2008.02.030","article-title":"Reporting late rectal toxicity in prostate cancer patients treated with curative radiation treatment","volume":"72","author":"Faria","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.07.014_bib0140","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.2021.39.6_suppl.248","article-title":"The stereotactic prostate radiotherapy (SPORT) trial: a randomized feasibility study comparing prostate SABR to prostate and pelvic nodal SABR","volume":"39","author":"Fairmichael","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.07.014_bib0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2022.05.050","article-title":"Acute and late adverse effects of prostate-only or pelvic stereotactic radiation therapy in prostate cancer: a comparative study","volume":"114","author":"Murthy","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.07.014_bib0150","series-title":"NRG-GU009 trial. Parallel phase III randomized trials for high risk prostate cancer evaluating de-intensification for lower genomic risk and intensification of concurrent therapy for higher genomic risk with radiation (Predict-RT*)","author":"Nguyen","year":"2022"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824000246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824000246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T14:59:23Z","timestamp":1713452363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321824000246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1278321824000246"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2023.07.014","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute toxicity in patients with high-risk prostate cancer treated with stereotactic body radiation, with irradiation to the prostate and pelvic nodes","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2023.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}